Navigating the opportunities and challenges in analytical development of flowcytometry for T cell therapy

T cell therapies are derived from autologous or allogeneic starting materials and target various diseases, including cancers, autoimmune diseases, and infectious diseases. This article highlights the rapid advancements in assay validation tools, focusing on flow cytometry as a crucial technique for analyzing T cell products. Understanding the intricacies of both T cell therapies and flow cytometry is essential for successful clinical and regulatory outcomes.